The $800 Million Pill and over one million other books are available for Amazon Kindle. Learn more
Buy Used
$4.34
FREE Shipping on orders over $35.
Used: Good | Details
Sold by owlsbooks
Condition: Used: Good
Comment: Book is used, fast shipping and great customer service.
Access codes and supplements are not guaranteed with used items.
Have one to sell? Sell on Amazon
Flip to back Flip to front
Listen Playing... Paused   You're listening to a sample of the Audible audio edition.
Learn more
See this image

The $800 Million Pill: The Truth behind the Cost of New Drugs Hardcover – April 22, 2004

ISBN-13: 978-0520239456 ISBN-10: 0520239458 Edition: 1st

Used
Price: $4.34
21 New from $0.95 54 Used from $0.01 2 Collectible from $14.95
Amazon Price New from Used from
Kindle
"Please retry"
Hardcover
"Please retry"
$0.95 $0.01
Free%20Two-Day%20Shipping%20for%20College%20Students%20with%20Amazon%20Student


Frequently Bought Together

The $800 Million Pill: The Truth behind the Cost of New Drugs + The Truth About the Drug Companies: How They Deceive Us and What to Do About It
Buy the selected items together

NO_CONTENT_IN_FEATURE

Best Books of the Month
Best Books of the Month
Want to know our Editors' picks for the best books of the month? Browse Best Books of the Month, featuring our favorite new books in more than a dozen categories.

Product Details

  • Hardcover: 297 pages
  • Publisher: University of California Press; 1 edition (April 22, 2004)
  • Language: English
  • ISBN-10: 0520239458
  • ISBN-13: 978-0520239456
  • Product Dimensions: 9.2 x 6.4 x 1 inches
  • Shipping Weight: 1.2 pounds
  • Average Customer Review: 4.1 out of 5 stars  See all reviews (15 customer reviews)
  • Amazon Best Sellers Rank: #1,603,959 in Books (See Top 100 in Books)

Editorial Reviews

From Publishers Weekly

In this fascinating critical look at drug and biotech companies, Goozner pulls back the curtain on the process of new drug development and answers two important questions: "where do new drugs come from?" and "what do they cost to invent?" Using case studies that recount the discovery, development and eventual commercialization of a number of significant drugs, including Epogen and the AIDS cocktail, Goozner dismantles the pharmaceutical industry’s assertion that drug prices must be kept high in order to stimulate cutting edge research. The cost of each new discovery averages $800 million, industry officials have claimed. But Goozner argues that citizens are already paying much of that bill: taxpayer-financed medical research, he finds, has played a major role in each important medical discovery. Goozner convincingly argues that new drugs get into the hands of the sick not thanks to drug and biotech companies, but to the passion of dedicated scientists—in both the private sector and the public. A former Chief Economics Correspondent for the Chicago Tribune and an award-winning journalist, Goozer writes with skill and elegance, incorporating anecdote and history in a way that enlivens his research and makes his book an engrossing read. Though the issue of drug costs has been discussed extensively in the media, Goozer’s study puts all the political chatter, news coverage and analysts’ reports into a context where they finally make sense.
Copyright © Reed Business Information, a division of Reed Elsevier Inc. All rights reserved.

From The New England Journal of Medicine

The pharmaceutical industry claims that it can continue playing a key role in the development of new weapons against disease only if Americans pay prices for medicines that yield very high profits. It also claims that price controls would cause the stream of new products to dry up. Merrill Goozner, a former chief economics correspondent at the Chicago Tribune, comes to a conclusion that is very different from the views espoused by the drug companies. He does so on the basis of a detailed review of the development of drugs to combat cancer and the human immunodeficiency virus, a description of the early successes of therapies developed by the biotechnology industry, and a review of the economics of "me-too" products, such as H(sub 2) antagonists, proton-pump inhibitors, and allergy medications. He believes that the private sector's main role is to develop and commercialize therapies that are based on knowledge generated by independent researchers in academia and in government. In his opinion, high prices and big profits are not the key ingredients in pharmaceutical breakthroughs. On one hand, this book gives the reader lots of interesting and useful background about the people and organizations involved in expanding medical knowledge and in developing drugs. On the other hand, it falls short of what I expected from the title. It is not a detailed forensic accounting of the true cost of developing individual drugs as compared with industry claims. Indeed, the only real discussion of the $800 million pill (the alleged average cost of developing a new drug in the United States) comes in a brief review of a study by the Tufts University Center for the Study of Drug Development that was first published in 1991 and then updated in 2001. There is a brief rebuttal from other organizations in the penultimate chapter of the book, but for a reader looking for definitive "proof" or data, this book falls short. Written in the typical style of investigative journalism, the book comes across as an author's attempt to prove a point, rather than an impartial scientist's effort to answer a question. Goozner repeatedly comes back to one central theme: that medical innovations start with dedicated and passionate people, most of whom are not employed by the pharmaceutical industry, who are investigating scientific questions. Without these dedicated scientists, none of the innovations described in this book would have occurred. In other words, the development of drugs is not exclusively driven by high profits but, rather, is a collection of efforts. Goozner goes on to suggest some very useful methods for improving the process of drug development with the support of government-funded research (e.g., randomized trials comparing new and existing products, such as the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, known as ALLHAT). Although the approach Goozner uses in this book is not scientific, I think he makes a persuasive case. The passion of individual scientists pursuing an activity they truly enjoy, not the profit motive, has led to the major technological advances of the past century. I will end by saying that I am not one who enjoys reading books slowly. I often skim. In order to read a book from cover to cover, I have to find it truly interesting. I can tell you that I read every word of this book. Allan S. Detsky, M.D., Ph.D.
Copyright © 2004 Massachusetts Medical Society. All rights reserved. The New England Journal of Medicine is a registered trademark of the MMS.

More About the Author

Discover books, learn about writers, read author blogs, and more.

Customer Reviews

4.1 out of 5 stars
Share your thoughts with other customers

Most Helpful Customer Reviews

56 of 60 people found the following review helpful By Joel M. Kauffman on November 2, 2004
Format: Hardcover
A masterful work on the exaggerations by Big Pharma on the cost of developing new prescription drugs. Tells detailed stories of the development of erythropoietin (Epo), Ceredase, Replagal, AZT and triple cocktail for AIDS, Cisplatin, Taxol, Erbitux, sulfanilamide, Tagamet, Zantac, Prilosec, Nexium and others. The stories are easy to understand and back up Goozner's contention that most real breakthroughs in drug development are the result of long years of work by academics or in government labs (NIH), and occcasionally by biotech firms, usually not by the Big Pharma companies.

Goozner confirms others in noting that about 4/5ths of "new" drugs, while being new molecules, are similar to others on the market. This consumes most of Big Pharma's research and sales dollars. He shows that simply purifying a drug to sell one of two isomers (left-handed, say, not mixed left- and right-handed) will get a new drug approval from the FDA (Nexium vs. Prilosec, I think). Sometimes this is valuable for patients, but not always. In ibuprofen it does not matter.

Goozner carefully works out the cost of a typical new drug launch at $100 to $200 million, a lot, but not $800. Many details are explained, such as orphan drugs, and access for compassionate use. Some of the perversions of drug trials are exposed, such as failure to compare a new drug with the best previous one. The limitations of newer NSAIDS (Celebrex, Vioxx) and many anticancer drugs are brought out.

This book has good good academic referencing and a good index. So why only 4 stars? The layout, some of the chemistry and some of the pharmacology.

Each paragraph is a gem of understandable prose.
Read more ›
1 Comment Was this review helpful to you? Yes No Sending feedback...
Thank you for your feedback. If this review is inappropriate, please let us know.
Sorry, we failed to record your vote. Please try again
3 of 3 people found the following review helpful By RJB on February 22, 2010
Format: Paperback Verified Purchase
In light of the healthcare debate, this book needs to be updated. The third section on Big Pharma is the real critical information part. I guess America likes the idea of heavy advertising and an army of drug sales people for the me-too drugs, reformulated prescriptions at the same ultra high prices, the lack of real innovation, the overlooking of true research dedication for obscure diseases, etc. This book is too important not to go into a new, expanded edition.
Comment Was this review helpful to you? Yes No Sending feedback...
Thank you for your feedback. If this review is inappropriate, please let us know.
Sorry, we failed to record your vote. Please try again
15 of 21 people found the following review helpful By A Customer on April 29, 2004
Format: Hardcover
I found this book fascinating, informative and thought-provoking. It examines how the current system for bringing new drugs to market works, what the short-comings of this system are, and how it could be improved to get more benefit from the money that tax-payers and users of health services (whether by paying directly for drugs or through insurance premiums)contribute.
Although this could have become a really dry exercise in economics or a political tirade agains drug companies, instead it contains a series of stories which track the development of some of the major "breakthrough" drugs in recent history. We are introduced to people who dedicated their lives to finding a cure for a single disease and read about the many set-backs and struggles that they had to go through to achieve this goal. The medical information that is explained in the course of these stories was, for me, one of the most interesting aspects of the book
Comment Was this review helpful to you? Yes No Sending feedback...
Thank you for your feedback. If this review is inappropriate, please let us know.
Sorry, we failed to record your vote. Please try again
1 of 1 people found the following review helpful By ane on July 28, 2013
Format: Hardcover
This is a well written and interesting book. I truly recommend it. I also feel irritated about the blatant lies that some of the critiques of this book have posted.I am a scientist working on drug-discovery in academia. I have also worked for small and big bio-parmaceutical companies, I came back to academia since I wanted to do creative research.
Through numerous detailed examples this book shows that drug companies are getting too much money for their miserable effectiveness. We all want the drug-companies to earn their money, and to live on a free market. Just like the big bankers, the drug-companies use political manipulations and FDA to take unnecessary too much money from the sick, who are often retired moms and paps. There is an exponential growth in lawsuits that drug-companies are engaged in, there is an exponential growth in tax breaks that the companies get for fictive research efforts, there is an exponential growth in marketing expenses. And yes, there is less and less research investments even with higher and higher product prices. The money is not going into creative research, but to manipulative practices.
At the end, this book has given due respect to the universities, which have been under constant attack as unnecessary expenses of government money.
Comment Was this review helpful to you? Yes No Sending feedback...
Thank you for your feedback. If this review is inappropriate, please let us know.
Sorry, we failed to record your vote. Please try again
1 of 2 people found the following review helpful By Paul J. Fitzgerald on November 29, 2007
Format: Paperback
This book is filled with detailed information on drug companies, development and marketing of drugs, federal regulation of drug companies, academic drug research, and some of the interesting characters involved in all of this. It comes across as slightly against big pharma, but not overly so. It may be a touch dry, with a touch more emphasis on the bureaucratic aspects of the drug development process, but definitely worth a read if you're interested in why prescription drugs cost so much in America and where this is all leading. Author of Adjust Your Brain: A Practical Theory for Maximizing Mental Health.
Comment Was this review helpful to you? Yes No Sending feedback...
Thank you for your feedback. If this review is inappropriate, please let us know.
Sorry, we failed to record your vote. Please try again

Most Recent Customer Reviews


What Other Items Do Customers Buy After Viewing This Item?